Navigation Links
Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
Date:5/28/2009

precision. Brain scans are administered at eight-week intervals post-treatment. Cotara has been generally well tolerated with an acceptable safety profile in clinical studies completed to date.

The main objectives of the open label Phase I dosing and dosimetry study at U.S. brain cancer centers are to confirm the maximum tolerated dose, to determine radiation dosimetry and to assess overall patient survival, progression free survival and the proportion of patients alive at six months following Cotara administration. Dosimetry data presented at the 2008 ASCO Annual Meeting showed that Cotara delivered 100-fold more radiation to the tumor as compared to other organs. Expanded data from this study has been accepted for an oral presentation at the Society of Nuclear Medicine Annual Meeting on June 16, 2009 in Toronto, Canada.

Cotara Presentation Details:

Reference #: 150240

Publication No.: 445

Abstract Title: Dosimetry of phase I interstitial 131I-chTNT-1/B MAb (Cotara) for the treatment of recurrent glioma

Accepted to: ISRTRD Integrated Session (Oral)

Session Info: Dosimetry/Radiobiology IV: Targeted, Diagnostic and Therapeutic Agents

Tuesday, June 16

12:30 PM - 2:00 PM

Room 701B

About Cotara(R)

Cotara is an experimental treatment for brain cancer that links a radioactive isotope to a targeted monoclonal antibody designed to bind to the DNA histone complex that is exposed by dead and dying cells found at the center of solid tumors. Cotara's targeting mechanism enables it to bind to the dying tumor cells, delivering its radioactive payload to the adjacent living tumor cells and essentially destroying the tumor from the inside out, with minimal radiation exposure to healthy tissue. Cotara is delivered using convection-enhanced delivery (CED), an NIH-developed method that targets the specific tumor site in the brain. In a
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
2. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
3. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
4. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
7. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
8. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
9. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
10. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
11. Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... HealthDay Reporter , MONDAY, Sept. 1, 2014 (HealthDay ... boost their heart health, cutting down on carbohydrates may work ... In a small clinical trial of obese adults, researchers found ... weight over a year than those who followed a low-fat ... and triglyceride levels, the research team reports in the Sept. ...
(Date:9/2/2014)... Moroccan Eco-Biologics’ new one-of-a-kind Vitality Hair Recovery ... the foundation of all natural Moroccan plant extracts to ... There is nothing similar to Vitality Hair Recovery cream ... is a commonly encountered problem for men and women ... been limited to existing medications offering mediocre results, considerable ...
(Date:9/2/2014)... September 02, 2014 Humility of Mary Health ... 18 at St. Elizabeth Health Center, 1044 Belmont Ave. , ... about more than 200 common health problems as well as ... and injury, and advice on when to seek medical attention. ... noon in the Youngstown Room; the evening session runs from ...
(Date:9/2/2014)... is pleased to announce that the following papers ... the ESC Congress 2014, taking place in Barcelona, ... Ultrathin strut biodegradable polymer sirolimus-eluting stent versus ... (BIOSCIENCE): a randomised, single-blind, non-inferiority trial, Windecker et ... strut thickness, surface polymer, and drug release have ...
(Date:9/2/2014)... NC (PRWEB) September 02, 2014 Researchers in ... woman who developed mesothelioma after being exposed to asbestos-contaminated work ... has all the details of the report in a new ... Doctors at the ESI Model Hospital say their patient was ... and breathlessness. Further investigation found that she had come in ...
Breaking Medicine News(10 mins):Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 3Health News:New All Natural, Organic Hair Recovery Products by Moroccan Eco-Biologics, Restore Lost Hair with No Side Effects 2Health News:HMHP Offers ‘Health at Home’ Workshop 2Health News:The Lancet: European Society of Cardiology Congress 2014 media alert 2Health News:New Report Illustrates That Even Brief Asbestos Exposure Can Trigger Mesothelioma, According to Surviving Mesothelioma 2
... , NEW YORK, Sept. 10 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) ... develops novel therapeutic proteins that disrupt the advance of ... in the process of acquiring three promising new drug ... in royalty fees in the mid to long term. ...
... , , , ... to those who are here illegally," President Obama said in a carefully ... last night. The problem, notes the Federation for American Immigration Reform (FAIR), ... Health Care Act of 2009, clearly would benefit illegal aliens. , ...
... , , SAN FRANCISCO, ... professional association in U.S. history took a major step forward ... Nurses Association/National Nurses Organization in San Francisco voted unanimously to ... National Nurses United, unifying the 86,000-member CNA/NNOC with the ...
... (GSA) invites all journalists to attend its 62nd Annual ... the field of aging from November 18 to 22 ... An estimated 3,500 professionals are expected to attend the ... Atlanta Marriott Marquis . The theme for 2009 is "Creative ...
... The University of Miami School of Nursing and Health Studies ... Foundation in the amount of $30,000 to support six students ... program. "Family nurse practitioners have a promising future" said Nilda ... Studies. "The Dr. John T. Macdonald Foundation grant will help ...
... , , LAKE FOREST, Ill., ... leading global specialty pharmaceutical and medication delivery company, today announced that ... on Thursday, Sept. 17, 2009. The company,s senior leadership team and ... , A streaming audio webcast of the event, ...
Cached Medicine News:Health News:GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees 2Health News:GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees 3Health News:President Obama Misleads Public on Health Care for Illegal Aliens; Illegal Aliens Would Benefit Under H.R. 3200 2Health News:California Nurses/NNOC, Nation's Largest Nurses' Organization, Unanimously Endorses Joining RN Super Union 2Health News:An invitation to the nation's premier aging conference 2Health News:UM receives grant to support graduate students in the family nurse practitioner program 2Health News:Hospira to Host 2009 Investor Day 2
(Date:9/2/2014)... 2014  VentiRx Pharmaceuticals, Inc., a clinical ... and commercialization of novel Toll-like receptor 8 ... Food and Drug Administration (FDA) has granted ... motolimod (VTX-2337) when administered in combination with ... of women with ovarian cancer whose disease ...
(Date:9/2/2014)...   Intrexon Corporation (NYSE: XON ... it has entered into an Exclusive Channel Collaboration (ECC) ... (EURONEXT: SAN and NYSE: SNY ) to ... of its marketed Active Pharmaceutical Ingredients (APIs) through Sanofi,s ... This collaboration will leverage Intrexon,s proprietary technology suite plus ...
(Date:9/2/2014)... , Sept. 2, 2014   Veracyte, Inc. (Nasdaq: ... Anderson , president and chief executive officer, will present in ... Healthcare Unplugged Conference 2014 on Monday, September 8, 2014 at ... The live audio webcast and subsequent replay may ... Please connect to the website at least 15 minutes prior ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3Veracyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014 2
... YORK, Sept. 1, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0559262/Global-CRO-Market-Quantitative-Assessment.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development This ... globally, by phase and market type, R&D ...
... This evening, Novo Nordisk awarded sponsorships totaling ... that educate people living with type 2 diabetes on ... risk of long-term diabetes related complications. The sponsorships are ... aims to promote enduring, sustainable change for people living ...
Cached Medicine Technology:Global CRO Market: Quantitative Assessment 2Global CRO Market: Quantitative Assessment 3Novo Nordisk Partners with Minneapolis Community Groups to Support Diabetes Education Programs 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: